Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen

AIDS

Volumn 22, Issue 15, 2008, Pages 2045-2051

  Roquebert, Bénédicte ^a,b   Blum, Laurent ^a   Collin, Gilles ^a   Damond, Florence ^a   Peytavin, Gilles ^a   Leleu, Juliette ^a   Matheron, Sophie ^b,c   Chêne, Geneviève ^a   Brun Vézinet, Françoise ^a,b   Descamps, Diane ^a,b  

^a BICHAT HOSPITAL   (France)

^b Hôpital René Dubos ^*

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AZATHIOPRINE; DARUNAVIR; ELVITEGRAVIR; INTEGRASE; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; PROTEINASE; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; TENOFOVIR; TIPRANAVIR;

ADULT; CASE REPORT; CD4 LYMPHOCYTE COUNT; DRUG TREATMENT FAILURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; LETTER; MALE; PRIORITY JOURNAL; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE;

DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-2; HUMANS; MALE; MIDDLE AGED; MUTATION; PYRROLIDINONES; TREATMENT FAILURE;

EID: 53549113615     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32830f4c7d     Document Type: Letter

References (10)

1. Withrouw M, Pannecouque C, Switzer WM, Folks TM, De Clercq E, Heneine W. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther 2004; 9:57-65.
2. Desbois D, Roquebert B, Peytavin G, et al. In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors. Antimicrob Agents Chemother 2008; 52:1545-1548.
3. Roquebert B, Damond F, Collin G, et al. Phenotypic susceptibility in vitro to raltegra vir and elvitegra vir and polymorphism of the integrase gene of HIV-2 clinical isolates. Proceedings of the XV Conference on Retroviruses and Opportunistic Infections; 2008; Boston, USA.
4. Damond F, Lariven S, Roquebert B, et al. Virological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected patients. AIDS 2008; 22:665-666.
5. Cooper D, Gatell J, Rockstroh J, et al. Results of BENCHMRK-1: a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistantvirus. Proceedings of the 14th Conference on Retroviruses and Opportunistic Infections; 25-28 February 2007; Los Angeles, CA.
6. Steigbigel R, Kumar P, Eron J, et al. Results of BENCHMRK-2: a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. Proceedings of the 14th Conference on Retroviruses and Opportunistic Infections; 25-28 February 2007; Los Angeles, CA.
7. Hazuda D, Miller MD, Nguyen BY, Zhao J. Resistance to the HIV-I integrase inhibitor raltegravir: analysis of protocol 005 a phase II study in patients with triple class resistant HIV-1 infection. Proceedings of the XVI International HIV Drug Resistance Workshop; 2007; Barbados.
8. Mc Coll D, Fransen S, Gupta S, et al. Resistance and cross resistance to first generation integrase inhibitors: insights from a phase II study of elvitegravir (GS-9137). Antivir Ther 2007; 12:S11.
9. Garrett N, Xub L, Smit E, et al. Raltegravir treatment response inan HIV-2 infected patient: a case report. AIDS 52008; 22:1091-1098.
10. Malet I, Delelis O, Valantin MA, et al. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother 2008; 52:1351-1358.